Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/120231
Title: | First-line treatment in lymphomatoid papulosis: a retrospective multicentre study |
Author: | Fernández de Misa, Ricardo Hernández Machín, B. Servitje Bedate, Octavio Valentí Medina, Francesc Maroñas Jiménez, L. Ortiz Romero, Pablo L. Sánchez Schmidt, Júlia Pujol, Ramon M. Gallardo, Fernando Pau Charles, I. Garcia-Muret, Maria P. Pérez Gala, S. Román, Concepción Cañueto, J. Blanch Rius, L. Izu, Rosa Ortiz Brugués, Ariadna Martí, Rosa M. Blanes, M. Morillo, Mercedes Sánchez, P. Peñate, Yerai Bastida, J. Pérez Gil, Amalia Lopez Lerma, Ingrid Muniesa Montserrat, Cristina Estrach Panella, Ma. Teresa (María Teresa) |
Keywords: | Limfomes Malalties de la pell Fototeràpia Lymphomas Skin diseases Phototherapy |
Issue Date: | Mar-2018 |
Publisher: | Wiley |
Abstract: | Background: Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce. Aim: To assess the daily clinical practice approach to LyP and the response to first-line treatments. Methods: This was a retrospective study enrolling 252 patients with LyP. Results: Topical steroids, methotrexate and phototherapy were the most common first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively. Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time to CR was 10 months (95% CI 6-13 months), and 78% of complete responders showed cutaneous relapse; both results were similar for all treatment groups (P > 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P < 0.03). Having the Type A LyP variant (RR = 2.04; 95% CI 0.96-4.30) and receiving a first-line treatment other than phototherapy (RR = 5.33; 95% CI 0.84-33.89) were significantly associated with cutaneous early relapse. Of the 252 patients, 31 (13%) had associated mycosis fungoides unrelated to therapeutic approach, type of LyP or T-cell receptor clonality. Conclusions: Current epidemiological, clinical and pathological data support previous results. Topical steroids, phototherapy and methotrexate are the most frequently prescribed first-line treatments. Although CR and cutaneous relapse rates do not differ between them, phototherapy achieves a longer DFS. Presence of Type A LyP and use of topical steroid or methotrexate were associated with an increased risk of early relapse. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1111/ced.13256. |
It is part of: | Clinical and Experimental Dermatology, 2018, vol. 43, num. 2, p. 137-143 |
URI: | http://hdl.handle.net/2445/120231 |
Related resource: | https://doi.org/10.1111/ced.13256 |
ISSN: | 0307-6938 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
674076.pdf | 221.46 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.